Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | Breast Cancer | Review

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

Authors: Chunguang Wang, Meiling Bai, Zhiguang Sun, Nan Yao, Aiting Zhang, Shengyu Guo, Zatollah Asemi

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

MicroRNAs (miRNAs) are a group of small non-coding RNAs that affect gene expression. The role of miRNAs in different types of cancers has been published and it was shown that several miRNAs are inappropriately expressed in different cancers. Among the mechanisms that can cause this lack of proper expression are epigenetics, chromosomal changes, polymorphisms or defects in processing proteins. Recent research shows that phytochemicals, including epigallocatechin-3-gallate (EGCG), exert important epigenetic-based anticancer effects such as pro-apoptotic or anti proliferative through miRNA gene silencing. Given that EGCG is able to modulate a variety of cancer-related process i.e., angiogenesis, proliferation, metastasis and apoptosis via targeting various miRNAs such as let-7, miR-16, and miR-210. The discovery of new miRNAs and the differences observed in their expression when exposed to EGCG provides evidence that targeting these miRNAs may be beneficial as a form of treatment. In this review, we aim to provide an overview, based on current knowledge, on how phytochemicals, including epigallocatechin-3-gallate, can be considered as potential miRNAs modulator to improve efficacy of current cancer treatments.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338–49.PubMed
3.
Maresso KC, Basen-Engquist K, Hawk E. Cancer epidemiology, prevention, and survivorship. In: Hagberg C, Gottumukkala V, Buggy D, editors. Perioperative care of the cancer patient. Amsterdam: Elsevier; 2023. p. 3–14.
4.
Colditz GA, Dart H. Cancer: epidemiology and associations between diet and cancer. Encyclopedia of human nutrition. 4th ed. Amsterdam: Elsevier; 2023. p. 146–53.
5.
Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol. 2020;324:113118.PubMed
6.
Cao K, Tait SW. Apoptosis and cancer: force awakens, phantom menace, or both? Int Rev Cell Mol Biol. 2018;337:135–52.PubMed
7.
Yamada S, Tsukamoto S, Huang Y, Makio A, Kumazoe M, Yamashita S, et al. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep. 2016;6:19225.PubMedPubMedCentral
8.
Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis. 2011;32(12):1881–9.PubMedPubMedCentral
9.
Zan L, Chen Q, Zhang L, Li X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25. Bioengineered. 2019;10(1):374–82.PubMedPubMedCentral
10.
Fix LN, Shah M, Efferth T, Farwell MA, Zhang B. MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genomics Proteomics. 2010;7(5):261–77.PubMed
11.
Bhardwaj V, Mandal AKA. Next-generation sequencing reveals the role of epigallocatechin-3-gallate in regulating putative novel and known microRNAs which target the MAPK pathway in non-small-cell lung cancer A549 cells. Molecules (Basel, Switzerland). 2019;24(2):368.PubMed
12.
Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys. 2010;501(1):65–72.PubMedPubMedCentral
13.
Landis-Piwowar KR, Kuhn DJ, Wan SB, Chen D, Chan TH, Dou QP. Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs. Int J Mol Med. 2005;15(4):735–42.PubMed
14.
Khandelwal A, Hall JA, Blagg BS. Synthesis and structure–activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J Org Chem. 2013;78(16):7859–84.PubMedPubMedCentral
15.
Matsubara S, Shibata H, Ishikawa F, Yokokura T, Takahashi M, Sugimura T, et al. Suppression of helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun. 2003;310(3):715–9.PubMed
16.
Bimonte S, Cascella M, Barbieri A, Arra C, Cuomo A. Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge. Infect Agent Cancer. 2020;15:2.PubMedPubMedCentral
17.
Das A, Haque I, Ray P, Ghosh A, Dutta D, Quadir M, et al. CCN5 activation by free or encapsulated EGCG is required to render triple-negative breast cancer cell viability and tumor progression. Pharmacol Res Perspect. 2021;9(2):e00753.PubMedPubMedCentral
18.
Deepak Singh D, Han I, Choi EH, Yadav DK. CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. Comput Struct Biotechnol J. 2021;19:2384–97.PubMedPubMedCentral
19.
Khan MA, Hussain A, Sundaram MK, Alalami U, Gunasekera D, Ramesh L, et al. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol Rep. 2015;33(4):1976–84.PubMed
20.
Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M, et al. Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells. J Cell Mol Med. 2012;16(3):520–30.PubMedPubMedCentral
21.
Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun. 2011;414(3):551–6.PubMedPubMedCentral
22.
Liu JD, Chen SH, Lin CL, Tsai SH, Liang YC. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem. 2001;83(4):631–42.PubMed
23.
Wu Y, Lin Y, Liu H, Li J. Inhibition of invasion and up-regulation of E-cadherin expression in human malignant melanoma cell line A375 by (-)-epigallocatechin-3-gallate. J Huazhong Univ Sci Technolog Med Sci. 2008;28(3):356–9.PubMed
24.
25.
Cheng Z, Zhang Z, Han Y, Wang J, Wang Y, Chen X, et al. A review on anti-cancer effect of green tea catechins. J Funct Foods. 2020;74:104172.
26.
Zhang L, Xie J, Gan R, Wu Z, Luo H, Chen X, et al. Synergistic inhibition of lung cancer cells by EGCG and NF-κB inhibitor BAY11-7082. J Cancer. 2019;10(26):6543–56.PubMedPubMedCentral
27.
Yan C, Yang J, Shen L, Chen X. Inhibitory effect of Epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch Gynecol Obstet. 2012;285(2):459–67.PubMed
28.
Zhang J, Lei Z, Huang Z, Zhang X, Zhou Y, Luo Z, et al. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget. 2016;7(48):79557–71.PubMedPubMedCentral
29.
Sharifi-Rad M, Pezzani R, Redaelli M, Zorzan M, Imran M, Ahmed Khalil A, et al. Preclinical pharmacological activities of epigallocatechin-3-gallate in signaling pathways: an update on cancer. Molecules. 2020;25(3):467.PubMedPubMedCentral
30.
Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, et al. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells Requirement of the transcriptional repressor HBP1. J Biol Chem. 2006;281(16):10865–75.PubMed
31.
Gu JW, Makey KL, Tucker KB, Chinchar E, Mao X, Pei I, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc Cell. 2013;5(1):9.PubMedPubMedCentral
32.
Singh DD, Verma R, Tripathi SK, Sahu R, Trivedi P, Yadav DK. Breast cancer transcriptional regulatory network reprogramming by using the CRISPR/Cas9 system: an oncogenetics perspective. Curr Top Med Chem. 2021;21(31):2800–13.PubMed
33.
Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2002;2(6):350–9.PubMed
34.
Neuhaus T, Pabst S, Stier S, Weber AA, Schrör K, Sachinidis A, et al. Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol. 2004;483(2–3):223–7.PubMed
35.
Min KJ, Kwon TK. Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integr Med Res. 2014;3(1):16–24.PubMed
36.
Schmidt M, Schmitz HJ, Baumgart A, Guédon D, Netsch MI, Kreuter MH, et al. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol. 2005;43(2):307–14.PubMed
37.
Yun SY, Kim SP, Song DK. Effects of (-)-epigallocatechin-3-gallate on pancreatic beta-cell damage in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006;541(1–2):115–21.PubMed
38.
Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med. 2006;144(1):68–71.PubMed
39.
Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, Salamé E, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol. 2005;17(10):1135–7.PubMed
40.
Abdul Rahman A, Wan Ngah WZ, Jamal R, Makpol S, Harun R, Mokhtar N. Inhibitory mechanism of combined hydroxychavicol with epigallocatechin-3-gallate against glioma cancer cell lines: a transcriptomic analysis. Front Pharmacol. 2022;13:844199.PubMedPubMedCentral
41.
Qin J, Fu M, Wang J, Huang F, Liu H, Huangfu M, et al. PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin-3-gallate in ovarian cancer. Oncol Rep. 2020;43(6):1885–96.PubMedPubMedCentral
42.
Pang JY, Zhao KJ, Wang JB, Ma ZJ, Xiao XH. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. J Zhejiang Univ Sci B. 2014;15(6):533–9.PubMedPubMedCentral
43.
Zhong L, Hu J, Shu W, Gao B, Xiong S. Epigallocatechin-3-gallate opposes HBV-induced incomplete autophagy by enhancing lysosomal acidification, which is unfavorable for HBV replication. Cell Death Dis. 2015;6(5):e1770.PubMedPubMedCentral
44.
Sabry D, Abdelaleem OO, El Amin Ali AM, Mohammed RA, Abdel-Hameed ND, Hassouna A, et al. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. Mol Biol Rep. 2019;46(2):2039–47.PubMed
45.
Zhao L, Liu S, Xu J, Li W, Duan G, Wang H, et al. A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells. Cell Death Dis. 2017;8(11):e3160.PubMedPubMedCentral
46.
Lewis KA, Jordan HR, Tollefsbol TO. Effects of SAHA and EGCG on growth potentiation of triple-negative breast cancer cells. Cancers (Basel). 2018;11(1):23.PubMed
47.
Wang J, Man GCW, Chan TH, Kwong J, Wang CC. A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer. Cancer Lett. 2018;412:10–20.PubMed
48.
Wei R, Mao L, Xu P, Zheng X, Hackman RM, Mackenzie GG, et al. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct. 2018;9(11):5682–96.PubMedPubMedCentral
49.
Huang CY, Han Z, Li X, Xie HH, Zhu SS. Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol Lett. 2017;14(3):3623–7.PubMedPubMedCentral
50.
Moradzadeh M, Hosseini A, Erfanian S, Rezaei H. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase. Pharmacol Rep. 2017;69(5):924–8.PubMed
51.
Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, et al. Dual targeted therapy with p53 siRNA and epigallocatechingallate in a triple negative breast cancer cell model. PLoS ONE. 2015;10(4):e0120936.PubMedPubMedCentral
52.
Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM, Zhou KY, et al. EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7 breast cancer cells. J buon. 2014;19(2):435–9.PubMed
53.
Park SB, Bae JW, Kim JM, Lee SG, Han M. Antiproliferative and apoptotic effect of epigallocatechin-3-gallate on Ishikawa cells is accompanied by sex steroid receptor downregulation. Int J Mol Med. 2012;30(5):1211–8.PubMed
54.
Sen T, Moulik S, Dutta A, Choudhury PR, Banerji A, Das S, et al. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 2009;84(7–8):194–204.PubMed
55.
Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther. 2006;5(6):1483–92.PubMed
56.
Huh SW, Bae SM, Kim YW, Lee JM, Namkoong SE, Lee IP, et al. Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol. 2004;94(3):760–8.PubMed
57.
Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Ramachandran Muralidharan A, Agiesh KB, et al. A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo. Front Pharmacol. 2023;14:1096614.PubMedPubMedCentral
58.
Khalil H, Tazi M, Caution K, Ahmed A, Kanneganti A, Assani K, et al. Aging is associated with hypermethylation of autophagy genes in macrophages. Epigenetics. 2016;11(5):381–8.PubMedPubMedCentral
59.
Wang CC, Xu H, Man GC, Zhang T, Chu KO, Chu CY, et al. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis. 2013;16(1):59–69.PubMed
60.
Laschke MW, Schwender C, Scheuer C, Vollmar B, Menger MD. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod. 2008;23(10):2308–18.PubMed
61.
Lee WJ, Shim J-Y, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005;68(4):1018–30.PubMed
62.
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Can Res. 2003;63(22):7563–70.
63.
Gu B, Ding Q, Xia G, Fang Z. EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression. Oncol Rep. 2009;21(3):635–40.PubMed
64.
Nandakumar V, Vaid M, Katiyar SK. (−)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p 16 INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis. 2011;32(4):537–44.PubMedPubMedCentral
65.
Lee Y-H, Kwak J, Choi H-K, Choi K-C, Kim S, Lee J, et al. EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int J Mol Med. 2012;30(1):69–74.PubMed
66.
Ko H, So Y, Jeon H, Jeong M-H, Choi H-K, Ryu S-H, et al. TGF-β1-induced epithelial–mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 2013;335(1):205–13.PubMed
67.
Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochem Biophys Acta. 2010;1803(11):1231–43.PubMed
68.
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.PubMed
69.
Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131(1):18–32.PubMedPubMedCentral
70.
Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer—new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21(3):470–9.PubMed
71.
Abdelgawad A, Mosbah A, Eissa LA. Expression of microRNA-155 and human telomerase reverse transcriptase in patients with bladder cancer. Egypt J Basic Appl Sci. 2020;7(1):315–22.
72.
Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009;285(2):116–26.PubMed
73.
Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol. 2020;13(1):1–14.
74.
Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015;8(368):re3.PubMed
75.
Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603–14.PubMedPubMedCentral
76.
O’connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10(2):111–22.PubMed
77.
Efferth T, Saeed ME, Kadioglu O, Seo E-J, Shirooie S, Mbaveng AT, et al. Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnol Adv. 2020;38:107342.PubMed
78.
Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discovery. 2015;14(2):111–29.PubMed
79.
Smanski MJ, Zhou H, Claesen J, Shen B, Fischbach MA, Voigt CA. Synthetic biology to access and expand nature’s chemical diversity. Nat Rev Microbiol. 2016;14(3):135–49.PubMedPubMedCentral
80.
Alnuqaydan AM, Rah B, Almutary AG, Chauhan SS. Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells. Am J Cancer Res. 2020;10(3):799.PubMedPubMedCentral
81.
Rah B, Nayak D, Rasool R, Chakraborty S, Katoch A, Amin H, et al. Reprogramming of molecular switching events in upr driven er stress: Scope for development of anticancer therapeutics. Curr Mol Med. 2016;16(8):690–701.PubMed
82.
Singh I, Amin H, Rah B, Goswami A. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer. Front Biosci (Schol Ed). 2013;5:231–46.PubMed
83.
Li S, Kuo H-CD, Yin R, Wu R, Liu X, Wang L, et al. Epigenetics/epigenomics of triterpenoids in cancer prevention and in health. Biochem Pharmacol. 2020;175:113890.PubMedPubMedCentral
84.
Khan H, Reale M, Ullah H, Sureda A, Tejada S, Wang Y, et al. Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions. Biotechnol Adv. 2020;38:107385.PubMed
85.
Yuan M, Zhang X, Zhang J, Wang K, Zhang Y, Shang W, et al. DC-SIGN–LEF1/TCF1–miR-185 feedback loop promotes colorectal cancer invasion and metastasis. Cell Death Differ. 2020;27(1):379–95.PubMed
86.
Gallardo M, Kemmerling U, Aguayo F, Bleak TC, Muñoz JP, Calaf GM. Curcumin rescues breast cells from epithelial-mesenchymal transition and invasion induced by anti-miR-34a. Int J Oncol. 2020;56(2):480–93.PubMed
87.
Han Z, Zhang J, Zhang K, Zhao Y. Curcumin inhibits cell viability, migration, and invasion of thymic carcinoma cells via downregulation of microRNA-27a. Phytother Res. 2020;34(7):1629–37.PubMed
88.
Qiang Z, Meng L, Yi C, Yu L, Chen W, Sha W. Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells. J Int Med Res. 2019;47(3):1288–97.PubMedPubMedCentral
89.
Venkatadri R, Muni T, Iyer A, Yakisich J, Azad N. Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell death Dis. 2016;7(2):e2104.PubMedPubMedCentral
90.
Zhao J, Fang Z, Zha Z, Sun Q, Wang H, Sun M, et al. Quercetin inhibits cell viability, migration and invasion by regulating miR-16/HOXA10 axis in oral cancer. Eur J Pharmacol. 2019;847:11–8.PubMed
91.
Zhang C, Hao Y, Sun Y, Liu P. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis. J Pharmacol Sci. 2019;140(2):128–36.PubMed
92.
Yang H, Wang M, Sun H, Zhu S, Jin J. Synergetic effect of EP1 receptor antagonist and (-)-Epigallocatechin-3-gallate in hepatocellular carcinoma. Pharmacology. 2019;104(5–6):267–75.PubMed
93.
Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C, Langston W, et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog. 2010;49(8):739–49.PubMed
94.
Cerezo-Guisado MI, Zur R, Lorenzo MJ, Risco A, Martín-Serrano MA, Alvarez-Barrientos A, et al. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG. Food Chem Toxicol. 2015;84:125–32.PubMed
95.
Shi J, Liu F, Zhang W, Liu X, Lin B, Tang X. Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells. Oncol Rep. 2015;33(6):2972–80.PubMed
96.
Qin J, Wang Y, Bai Y, Yang K, Mao Q, Lin Y, et al. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Mol Med Rep. 2012;6(5):1040–4.PubMed
97.
Ma J, Shi M, Li G, Wang N, Wei J, Wang T, et al. Regulation of Id1 expression by epigallocatechin-3-gallate and its effect on the proliferation and apoptosis of poorly differentiated AGS gastric cancer cells. Int J Oncol. 2013;43(4):1052–8.PubMedPubMedCentral
98.
Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, et al. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol. 2006;44(6):1074–82.PubMed
99.
Zhu Y, Huang Y, Liu M, Yan Q, Zhao W, Yang P, et al. Epigallocatechin gallate inhibits cell growth and regulates miRNA expression in cervical carcinoma cell lines infected with different high-risk human papillomavirus subtypes. Exp Ther Med. 2019;17(3):1742–8.PubMed
100.
Allegri L, Rosignolo F, Mio C, Filetti S, Baldan F, Damante G. Effects of nutraceuticals on anaplastic thyroid cancer cells. J Cancer Res Clin Oncol. 2018;144:285–94.PubMed
101.
Appari M, Babu KR, Kaczorowski A, Gross W, Herr I. Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Int J Oncol. 2014;45(4):1391–400.PubMedPubMedCentral
102.
Banerjee S, Mandal AKA. Role of epigallocatechin-3-gallate in the regulation of known and novel microRNAs in breast carcinoma cells. Front Genet. 2022;13:995046.PubMedPubMedCentral
103.
Chakrabarti M, Ai W, Banik NL, Ray SK. Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells. Neurochem Res. 2013;38(2):420–32.PubMed
104.
Ahmed F, Ijaz B, Ahmad Z, Farooq N, Sarwar MB, Husnain T. Modification of miRNA Expression through plant extracts and compounds against breast cancer: Mechanism and translational significance. Phytomedicine. 2020;68:153168.PubMed
105.
Chakrabarti M, Ai W, Banik NL, Ray SK. Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells. Neurochem Res. 2013;38:420–32.PubMed
106.
Jang J-Y, Lee J-K, Jeon Y-K, Kim C-W. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. BMC Cancer. 2013;13(1):1–12.
107.
Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M, et al. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells. Mol Carcinog. 2018;57(12):1835–44.PubMed
108.
Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M, et al. Epigallocatechin-3-gallate inhibited cancer stem cell–like properties by targeting hsa-mir-485-5p/RXRα in lung cancer. J Cell Biochem. 2018;119(10):8623–35.PubMed
109.
Kang Q, Tong Y, Gowd V, Wang M, Chen F, Cheng K-W. Oral administration of EGCG solution equivalent to daily achievable dosages of regular tea drinkers effectively suppresses miR483-3p induced metastasis of hepatocellular carcinoma cells in mice. Food Funct. 2021;12(8):3381–92.PubMed
110.
La X, Zhang L, Li Z, Li H, Yang Y. (−)-Epigallocatechin Gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-κB/miR-155-5p/MDR1 pathway. J Agric Food Chem. 2019;67(9):2510–8.PubMed
111.
Lee H-Y, Chen Y-J, Chang W-A, Li W-M, Ke H-L, Wu W-J, et al. Effects of Epigallocatechin Gallate (EGCG) on urinary bladder urothelial carcinoma-next-generation sequencing and bioinformatics approaches. Medicina. 2019;55(12):768.PubMedPubMedCentral
112.
Li B-B, Huang G-L, Li H-H, Kong X, He Z-W. Epigallocatechin-3-gallate modulates microrna expression profiles in human nasopharyngeal carcinoma CNE2 cells. Chin Med J. 2017;130(01):93–9.PubMedPubMedCentral
113.
Lin C-H, Wang H-H, Chen T-H, Chiang M-C, Hung P-H, Chen Y-J. Involvement of microrna-296 in the inhibitory effect of epigallocatechin gallate against the migratory properties of anoikis-resistant nasopharyngeal carcinoma cells. Cancers. 2020;12(4):973.PubMedPubMedCentral
114.
115.
Fatemeh S, Katayoun DA. Efficacy of green tea extract on PC3 prostate cancer cells through upregulation of miR-195 expression and suppression of epithelial to mesenchymal transition. J Tradit Chin Med. 2022;42(5):681.PubMedCentral
116.
Safari F, Azad NR, Ezdiny AA, Pakizehkar S, Koohpar ZK, Ranji N. Antitumor activities of green tea by up-regulation of miR-181a expression in LNCaP cells using 3D cell culture model. Avicenna J Med Biotechnol. 2022;14(1):89.PubMedPubMedCentral
117.
Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011;25(4):1198.PubMedPubMedCentral
118.
Toden S, Tran H-M, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7(13):16158.PubMedPubMedCentral
119.
Wu K, Wei Y, Yu Y, Shan M, Tang Y, Sun Y. Green tea polyphenols inhibit malignant melanoma progression via regulating circ_MITF/miR-30e-3p/HDAC2 axis. Biotechnol Appl Biochem. 2022;69(2):808–21.PubMed
120.
Yamada S, Tsukamoto S, Huang Y, Makio A, Kumazoe M, Yamashita S, et al. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep. 2016;6(1):19225.PubMedPubMedCentral
121.
Yu C-C, Chen P-N, Peng C-Y, Yu C-H, Chou M-Y. Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget. 2016;7(15):20180.PubMedPubMedCentral
122.
Zhong Z, Dong Z, Yang L, Chen X, Gong Z. Inhibition of proliferation of human lung cancer cells by green tea catechins is mediated by upregulation of let-7. Exp Ther Med. 2012;4(2):267–72.PubMedPubMedCentral
123.
Zhou D-H, Wang X, Feng Q. EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer. 2014;66(4):636–44.PubMed
124.
Zhou J, Lei Y, Chen J, Zhou X. Potential ameliorative effects of epigallocatechin-3-gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. Int Immunopharmacol. 2018;64:162–9.PubMed
Metadata
Title
Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs
Authors
Chunguang Wang
Meiling Bai
Zhiguang Sun
Nan Yao
Aiting Zhang
Shengyu Guo
Zatollah Asemi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03081-8

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Review

Novel insights into mutual regulation between N6-methyladenosine modification and LncRNAs in tumors

Review

Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics

Research

Ubiquitin-specific peptidase 5 facilitates cancer stem cell-like properties in lung cancer by deubiquitinating β-catenin

Review

Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering

Review

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Review

Recent advances in the detection of glioblastoma, from imaging-based methods to proteomics and biosensors: A narrative review

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits